Literature DB >> 24304136

Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.

J P Pandey1, A M Namboodiri, Y Ohue, M Oka, E Nakayama.   

Abstract

GM (γ marker) allotypes, genetic variants of immunoglobulin γ chains, have been reported to be associated strongly with susceptibility to lung cancer, but the mechanism(s) underlying this association is not known. One mechanism could involve their contribution to humoral immunity to lung tumour-associated antigens. In this study, we aimed to determine whether particular GM and KM (κ marker) allotypes were associated with antibody responsiveness to XAGE-1b, a highly immunogenic lung tumour-associated cancer-testis antigen. Sera from 89 patients with non-small cell lung cancer (NSCLC) were allotyped for eight GM and two KM determinants and characterized for antibodies to a synthetic XAGE-1b protein. The distribution of various GM phenotypes was significantly different between XAGE-1b antibody-positive and -negative patients (P = 0·023), as well as in the subgroup of XAGE-1b antigen-positive advanced NSCLC (P = 0·007). None of the patients with the GM 1,17 21 phenotype was positive for the XAGE-1b antibody. In patients with antigen-positive advanced disease, the prevalence of GM 1,2,17 21 was significantly higher in the antibody-positive group than in those who lacked the XAGE-1b antibody (P = 0·026). This phenotype also interacted with a particular KM phenotype: subjects with GM 1,2,17 21 and KM 3,3 phenotypes were almost four times (odds ratio = 3·8) as likely to be positive for the XAGE-1b antibody as the subjects who lacked these phenotypes. This is the first report presenting evidence for the involvement of immunoglobulin allotypes in immunity to a cancer-testis antigen, which has important implications for XAGE-1b-based immunotherapeutic interventions in lung adenocarcinoma.
© 2013 British Society for Immunology.

Entities:  

Keywords:  GM/KM allotypes; XAGE-1b (GAGED2a); cancer-testis antigen; humoral immunity; non-small cell lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24304136      PMCID: PMC3958156          DOI: 10.1111/cei.12247

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

Review 1.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

Review 2.  Advances in human immunoglobulin allotypes.

Authors:  R Grubb
Journal:  Exp Clin Immunogenet       Date:  1995

3.  IgG and FcγR genotypes and humoral immunity to mucin 1 in prostate cancer.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Emily Kistner-Griffin
Journal:  Hum Immunol       Date:  2013-04-22       Impact factor: 2.850

4.  Genetic markers of immunoglobulin G and susceptibility to breast cancer.

Authors:  Janardan P Pandey; Emily Kistner-Griffin; Motoki Iwasaki; Shizhong Bu; Ray Deepe; Laurel Black; Yoshio Kasuga; Gerson S Hamada; Shoichiro Tsugane
Journal:  Hum Immunol       Date:  2012-08-09       Impact factor: 2.850

5.  Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins.

Authors:  J P Pandey; Z Prohászka; A Veres; G Füst; M Hurme
Journal:  Genes Immun       Date:  2004-01       Impact factor: 2.676

6.  Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer.

Authors:  J P Pandey; A M Namboodiri; E Kistner-Griffin; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

7.  A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer.

Authors:  Janardan P Pandey; Paul J Nietert; Kersti Klaamas; Oleg Kurtenkov
Journal:  Cancer Immunol Immunother       Date:  2009-04-14       Impact factor: 6.968

8.  Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma.

Authors:  Ali Mohamed Ali Eldib; Toshiro Ono; Michihide Shimono; Miho Kaneko; Kazuhiko Nakagawa; Ryo Tanaka; Yuji Noguchi; Eiichi Nakayama
Journal:  Int J Cancer       Date:  2004-02-10       Impact factor: 7.396

9.  A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.

Authors:  Kouya Shiraishi; Hideo Kunitoh; Yataro Daigo; Atsushi Takahashi; Koichi Goto; Hiromi Sakamoto; Sumiko Ohnami; Yoko Shimada; Kyota Ashikawa; Akira Saito; Shun-ichi Watanabe; Koji Tsuta; Naoyuki Kamatani; Teruhiko Yoshida; Yusuke Nakamura; Jun Yokota; Michiaki Kubo; Takashi Kohno
Journal:  Nat Genet       Date:  2012-07-15       Impact factor: 38.330

10.  Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma.

Authors:  J P Pandey; B T Shannon; K Y Tsang; H H Fudenberg; J G Camblin
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  2 in total

1.  Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.

Authors:  Yoshihiro Ohue; Hisashi Wada; Mikio Oka; Eiichi Nakayama
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer.

Authors:  Shi Jin; Shoubo Cao; Aleksei Grigorev; Jianhua Li; Qingwei Meng; Chunyan Wang; Meiyan Feng; Jing Hu; Feng Jiang; Yan Yu
Journal:  Cancer Manag Res       Date:  2018-07-16       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.